Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 21, Issue 43, Pages 12322
Publisher
Baishideng Publishing Group Inc.
Online
2016-03-12
DOI
10.3748/wjg.v21.i43.12322
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
- (2015) Lucrezia Laterza et al. EXPERT OPINION ON PHARMACOTHERAPY
- Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy
- (2015) Jasmohan S. Bajaj et al. HEPATOLOGY
- Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia
- (2015) Georgios N. Kalambokis et al. LIVER INTERNATIONAL
- Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
- (2014) J. S. Bajaj et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function
- (2014) Jasmohan S. Bajaj et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics
- (2014) Sari Tuomisto et al. BMC GASTROENTEROLOGY
- Is Rifaximin Effective in Maintaining Remission in Crohn's Disease?
- (2014) Anca Olivia Jigaranu et al. DIGESTIVE DISEASES
- Meta'omic Analytic Techniques for Studying the Intestinal Microbiome
- (2014) Xochitl C. Morgan et al. GASTROENTEROLOGY
- Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed
- (2014) Sudhir Maharshi et al. GUT
- Rifaximin: beyond the traditional antibiotic activity
- (2014) Fiorella Calanni et al. JOURNAL OF ANTIBIOTICS
- Alterations of the human gut microbiome in liver cirrhosis
- (2014) Nan Qin et al. NATURE
- Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers
- (2014) Corrado Blandizzi et al. PHARMACOLOGICAL RESEARCH
- Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites
- (2014) Philipp Lutz et al. PLoS One
- Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis
- (2014) Valerio Giannelli WORLD JOURNAL OF GASTROENTEROLOGY
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
- (2014) Kapil Sharma et al. Saudi Journal of Gastroenterology
- Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
- (2014) Rossella Cianci et al. Journal of Immunology Research
- A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy
- (2013) Barjesh Chander Sharma et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing
- (2013) Zhigang Zhang et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach
- (2013) Xiao Wei et al. BMC GASTROENTEROLOGY
- Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy
- (2013) Kevin D. Mullen et al. Clinical Gastroenterology and Hepatology
- Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats
- (2013) Dabo Xu et al. GASTROENTEROLOGY
- Pathological bacterial translocation in liver cirrhosis
- (2013) Reiner Wiest et al. JOURNAL OF HEPATOLOGY
- Altered profile of human gut microbiome is associated with cirrhosis and its complications
- (2013) Jasmohan S. Bajaj et al. JOURNAL OF HEPATOLOGY
- Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
- (2013) Jasmohan S. Bajaj et al. PLoS One
- Ascitic Microbiota Composition Is Correlated with Clinical Severity in Cirrhosis with Portal Hypertension
- (2013) Geraint B. Rogers et al. PLoS One
- New strategies for the management of diverticular disease: insights for the clinician
- (2013) Wen Boynton et al. Therapeutic Advances in Gastroenterology
- Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation
- (2012) Jasmohan S. Bajaj et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain
- (2012) Martina Bielaszewska et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver Center
- (2012) Puneeta Tandon et al. Clinical Gastroenterology and Hepatology
- Rifaximin for the treatment of irritable bowel syndrome
- (2012) Filippo Cremonini et al. EXPERT OPINION ON PHARMACOTHERAPY
- The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis
- (2012) Mohamad A. Hanouneh et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis
- (2012) Jiannis Vlachogiannakos et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study
- (2011) A. Sanyal et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Rifaximin Therapy in Minimal Hepatic Encephalopathy Cirrhotics
- (2011) Angelo Zullo et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Linkage of gut microbiome with cognition in hepatic encephalopathy
- (2011) Jasmohan S. Bajaj et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Inflammation and gastrointestinal Candida colonization
- (2011) Carol A Kumamoto CURRENT OPINION IN MICROBIOLOGY
- Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells
- (2011) Andrea Mencarelli et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
- (2011) Cosimo Prantera et al. GASTROENTEROLOGY
- Characterization of fecal microbial communities in patients with liver cirrhosis
- (2011) Yanfei Chen et al. HEPATOLOGY
- Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis
- (2011) Georgios N. Kalambokis et al. HEPATOLOGY
- Durability of Rifaximin Response in Hepatic Encephalopathy
- (2011) Guy W. Neff et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection
- (2011) Haifeng Lu et al. MICROBIAL ECOLOGY
- Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
- (2011) Mark Pimentel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rifaximin in the treatment of inflammatory bowel disease
- (2011) Mario Guslandi WORLD JOURNAL OF GASTROENTEROLOGY
- Rifaximin Improves Psychometric Performance and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy (The RIME Trial)
- (2010) Sandeep Singh Sidhu et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Characterisation of bacteria in ascites—reporting the potential of culture-independent, molecular analysis
- (2010) G. B. Rogers et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy
- (2010) Jasmohan S. Bajaj et al. GASTROENTEROLOGY
- Drug therapy: Rifaximin1
- (2010) Jasmohan S. Bajaj et al. HEPATOLOGY
- Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system
- (2010) Simone Maccaferri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas
- (2010) Z-D Jiang et al. JOURNAL OF CLINICAL PATHOLOGY
- Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?
- (2010) Georgios Kalambokis et al. MEDICAL HYPOTHESES
- Rifaximin Treatment in Hepatic Encephalopathy
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Rifaximin Treatment in Hepatic Encephalopathy
- (2010) Nathan M. Bass et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis
- (2009) J. VLACHOGIANNAKOS et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles
- (2009) E. L. Brown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease: A Case Series
- (2008) AMERICAN JOURNAL OF GASTROENTEROLOGY
- Immunoregulatory activity of rifaximin associated with a resistant mutant of Bifidobacterium infantis
- (2008) Beatrice Vitali et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started